News summary

New three-year real-world data on Leqembi® presented at CTAD 2026

Source: PR Newswire • Published: 18 Nov 2026, 16:42

Summarized by Masters of Longevity from PR Newswire.

LEADER real-world analysis found 76% lower dementia progression through 36 months.

New three-year real-world data on Leqembi® presented at CTAD 2026
Key Takeaways
  • Leqembi-treated patients showed a 76% lower progression rate.
  • Ninety-one point seven percent remained on Leqembi at 18 months.
  • Real-world evidence was subject to bias and data inconsistency.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.MoL PickMelatonin and Heart Failure: What the Evidence Actually ShowsA 2025 study linked melatonin use with heart failure. A 2026 analysis found no significant association. Their different designs explain why the question remains open.